secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-255200
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
--------------------------------------------------------------------------------

- Completed successful end-of-Phase 2 meeting with FDA for bitopertin in EPP, reaching alignment on all proposed study parameters with potential for accelerated approval.
- Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in NDD-CKD patients with anemia at ASN Kidney Week 2024.
- Ended Q3 2024 with $487M cash; closed $200M non-dilutive debt financing with Hercules Capital in November 2024.
- Net loss was $26.6M for Q3 2024, compared to $14.1M for same period in 2023.
- Appointed Steve Caffé as Chief Regulatory Officer and Rahul Kaushik as Chief Technical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524255200/0001193125-24-255200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524255200/d911918d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-255200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer